Heikki A Kuusanmäki

This study uses scRNA-seq to analyze AML patient samples across disease stages, identifying immune dysregulation and potential therapeutic targets.

This study evaluates small molecule STAT3/5 inhibitors for treating AML and NKCL, showing growth arrest and synergy with existing therapies in vitro and in vivo.

The paper develops a machine learning model to identify patient-specific multi-targeting therapies using single-cell transcriptomic data for hematological cancers and solid tumors.

This paper develops a computational-experimental approach to design patient-specific drug combinations for AML that are synergistic and minimally toxic.